Objective:Pseudomonas aeruginosa bloodstream infection presents a severe challenge to hospitalized patients. To investigate the clinical characteristics, risk factors and drug resistance of Pseudomonas aeruginosa bloodstream infection. Methods: Clinical data and laboratory results of patients with Pseudomonas aeruginosa bloodstream infection in the First Affiliated Hospital of Yangtze University from January 2019 to December 2022 were retrospectively analyzed. The factors associated with infection and death were analyzed by univariate analysis. Results: A total of 55 patients were enrolled in this study, The 28-day mortality rate was 14.5%. Univariate analysis showed that high procalcitonin, low albumin, ICU admission, central venous catheterization, indwelling catheter, and mechanical ventilation were associated with death. Multivariate Logistic regression analysis showed that hypoproteinemia and central venous catheters were independent risk factors for death in patients with Pseudomonas aeruginosa bloodstream infection. Conclusions: The drug resistance of P. aeruginosa bloodstream infection is not high, but the fatality rate is high. The combination of hypoalbuminemia after the onset of the disease and the use of central vein catheters can lead to increased mortality, suggesting that clinical identification of high-risk patients as early as possible, reducing the use of catheters, preventing the occurrence of P. aeruginosa bloodstream infection and improving the prognosis.
References
[1]
Liu, T., Zhang, Y. and Wan, Q. (2018) Pseudomonas aeruginosa Bacteremia among Liver Transplant Recipients. Infection and Drug Resistance, 11, 2345-2356. https://doi.org/10.2147/IDR.S180283
[2]
Micek, S.T., Wunderink, R.G., Kollef, M.H., et al. (2015) An International Multicenter Retrospective Study of Pseudomonas aeruginosa Nosocomial Pneumonia: Impact of Multidrug Resistance. Critical Care, 19, Article No. 219. https://doi.org/10.1186/s13054-015-0926-5
[3]
Horcajada, J.P., Montero, M., Oliver, A., et al. (2019) Epidemiology and Treatment of Multidrug-Resistant and Extensively Drug-Resistant Pseudomonas aeruginosa Infections. Clinical Microbiology Reviews, 32, e00031-19. https://doi.org/10.1128/CMR.00031-19
[4]
Oliver, A., Mulet, X., Lopez-Causape, C., et al. (2015) The Increasing Threat of Pseudomonas aeruginosa High-Risk Clones. Drug Resistance Updates, 21-22, 41-59. https://doi.org/10.1016/j.drup.2015.08.002
[5]
Ammerlaan, H.S., Harbarth, S., Buiting, A.G., et al. (2013) Secular Trends in Nosocomial Bloodstream Infections: Antibiotic-Resistant Bacteria Increase the Total Burden of Infection. Clinical Infectious Diseases, 56, 798-805. https://doi.org/10.1093/cid/cis1006
[6]
Fu, P., Guo, Y., Zhu, D.M., et al. (2022) 2021 CHINET China Bacterial Drug Resistance Surveillance. Chinese Journal of Infection and Chemotherapy, 5, 521-530.
[7]
Wang, P., Beitian, M., Jin, W.P., Wang, H.B. and Jiang, W. (2023) Distribution and Drug Resistance Analysis of Pathogenic Bacteria in Bloodstream Infections during 2012-2021. Chinese Journal of Antibiotics, 4, 445-452.
[8]
Chen, Y.B., Ji, J.R. and Liu, Z.Y. (2023) National Bacterial Resistance in Bloodstream Infections Surveillance (BRICS) 2021 Annual Report. Chinese Journal of Clinical Infectious Diseases, 1, 33-47.
[9]
Du, X.L., Zhou, H., Fu, Y.T., Yang, Q. and Zhou, J.Y. (2020) Analysis of Bacterial Resistance and Prognostic Factors Affecting Patients with Pseudomonas aeruginosa Bloodstream Infection. Chinese Journal of Infection and Chemotherapy, 2, 118-124
[10]
Tam, V.H., Chang, K.T., Abdelraouf, K., et al. (2010) Prevalence, Resistance Mechanisms, and Susceptibility of Multidrug-Resistant Bloodstream Isolates of Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 54, 1160-1164. https://doi.org/10.1128/AAC.01446-09
[11]
Khaledi, A., Schniederjans, M., Pohl, S., et al. (2016) Transcriptome Profiling of Antimicrobial Resistance in Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 60, 4722-4733. https://doi.org/10.1128/AAC.00075-16
[12]
Tuon, F.F., Lucas, L.W. and Rocha, J.L. (2012) Risk Factors of Pan Resistant Pseudomonas aeruginosa Bacteremia and the Adequacy of Antibiotic Therapy. The Brazilian Journal of Infectious Diseases, 16, 351-356. https://doi.org/10.1016/j.bjid.2012.06.009
[13]
Su, D.M., Huang, Y., Liu, Y., et al. (2017) Clinical Characteristics Analysis of Multi-Drug Resistant Patients with Pseudomonas aeruginosa Bloodstream Infection. Journal of the PLA Medical College, 38, 136-139.
[14]
Miao, K.-C., Su, Q.Q., Zhang, Y.Y., et al. (2018) Clinical Analysis of 251 Cases of Pseudomonas aeruginosa Bloodstream Infection. Chinese Journal of Infection and Chemotherapy, 18, 568-573.
[15]
Viasus, D., Puerta-Alcalde, P., Cardozo, C., et al. (2020) Predictors of Multidrug-Resistant Pseudomonas aeruginosa in Neutropenic Patients with Bloodstream Infection. Clinical Microbiology and Infection, 26, 345-350. https://doi.org/10.1016/j.cmi.2019.07.002
[16]
Rojas, A., Paacios-Baena, Z.R., Lopez-Cortes, L.E., et al. (2019) Rates, Predictors and Mortality of Community-Onset Bloodstream Infections Due to Pseudomonas aeruginosa: Systematic Review and Meta-Analysis. Clinical Microbiology and Infection, 25, 964-970. https://doi.org/10.1016/j.cmi.2019.04.005
[17]
Babich, T., Naucler, P., Valik, J.K., et al. (2020) Risk factors for Mortality among Patients with Pseudomonas aeruginosa Bacteraemia: A Retrospective Multicentre Study. International Journal of Antimicrobial Agents, 55, Article ID: 105847. https://doi.org/10.1016/j.ijantimicag.2019.11.004
[18]
Zhang, Y.L., Li, Y., Zeng, J., et al. (2020) Pseudomonas aeruginosa Risk Factors for Mortality of Inpatients with Bacteremia in China: Impact of Resistance Profile in the Mortality. Infection and Drug Resistance, 13, 4115-4123. https://doi.org/10.2147/IDR.S268744
[19]
Xiong, L.L., Ma, Q., Yuan, Y.H., Zhang, T. and Li, Y. (2021) Risk Factor Analysis of Mortality in 57 Cases of Pseudomonas aeruginosa Bloodstream Infection. Chinese Journal of Infection and Chemotherapy, 3, 254-257.
